ImmunityBio Inc Ordinary Shares IBRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IBRX is a good fit for your portfolio.
News
-
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
-
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
-
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
-
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
-
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva
-
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
-
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
-
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
Trading Information
- Previous Close Price
- $8.26
- Day Range
- $7.68–8.14
- 52-Week Range
- $1.25–10.53
- Bid/Ask
- $7.72 / $7.75
- Market Cap
- $5.36 Bil
- Volume/Avg
- 5.2 Mil / 7.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6,753.88
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 628
- Website
- https://www.immunitybio.com
Comparables
Valuation
|
Metric
|
IBRX
|
ACLX
|
EQRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 5.65 | 0.97 |
Price/Sales | 6,753.88 | 22.84 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IBRX
|
ACLX
|
EQRX
|
|---|---|---|---|
Quick Ratio | 4.63 | 5.94 | 18.43 |
Current Ratio | 5.05 | 6.06 | 18.78 |
Interest Coverage | −3.53 | −23.39 | — |
Quick Ratio
IBRX
ACLX
EQRX
Profitability
|
Metric
|
IBRX
|
ACLX
|
EQRX
|
|---|---|---|---|
Return on Assets (Normalized) | −125.30% | −6.26% | −15.72% |
Return on Equity (Normalized) | — | −12.08% | −16.71% |
Return on Invested Capital (Normalized) | −157.68% | −13.11% | −21.31% |
Return on Assets
IBRX
ACLX
EQRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lhxxbkdgq | Ddwt | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dmyxhjf | Qzkvl | $105.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Llgdcvdg | Rcblb | $105.3 Bil | |
MRNA
| Moderna Inc | Lhwtxkyvh | Xqhw | $46.4 Bil | |
ARGX
| argenx SE ADR | Lbpkzglzx | Tbj | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Xbjvbbr | Vsnvl | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vrrybbpk | Gwdqrj | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bncyknzq | Zkzwff | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gddlzjhd | Zsmml | $12.6 Bil | |
INCY
| Incyte Corp | Jwhmxnzmb | Fbxlvzl | $12.0 Bil |